HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

KHK4083

anti-OX40 (CD134) monoclonal antibody developed for the treatment of plaque psoriasis

Networked: 5 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Shimabe, Munetake: 2 articles (01/2021 - 08/2020)
2.	Furihata, Kenichi: 1 article (01/2021)
3.	Ishiguro, Yoh: 1 article (01/2021)
4.	Ito, Hiroaki: 1 article (01/2021)
5.	Kaneko, Etsuji: 1 article (01/2021)
6.	Katsushima, Shinji: 1 article (01/2021)
7.	Morishige, Takuya: 1 article (01/2021)
8.	Mukai, Mayumi: 1 article (01/2021)
9.	Watanabe, Risa: 1 article (01/2021)
10.	Yoshimura, Naoki: 1 article (01/2021)

Related Diseases

1.	Ulcerative Colitis 07/01/2020 - "We aimed to assess the safety and preliminary efficacy of KHK4083 in patients with moderately active ulcerative colitis (UC). " 01/01/2021 - "A Phase 1 Study of KHK4083: A Single-Blind, Randomized, Placebo-Controlled Single-Ascending-Dose Study in Healthy Adults and an Open-Label Multiple-Dose Study in Patients With Ulcerative Colitis." 10/01/2020 - "Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis." 07/01/2020 - "Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis."
2.	Atopic Dermatitis (Atopic Eczema) 08/01/2020 - "KHK4083, a fully human anti-OX40 monoclonal antibody, is a potential novel therapeutic option for moderate to severe atopic dermatitis (AD), targeting the immunopathogenic pathways. " 08/01/2020 - "Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis."
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 08/01/2017 - "The primary aim of this first-in-human phase 1 study was to determine the safety and tolerability of ascending single doses of KHK4083 in patients with mild to moderate plaque psoriasis. " 08/01/2017 - "KHK4083 administration as a single dose up to 10 mg/kg IV or 1.0 mg/kg SC was generally safe and well tolerated in patients with mild to moderate plaque psoriasis with no dose-limiting AEs." 08/01/2017 - "Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis."
4.	Chills 08/01/2017 - "The most frequent treatment-related AEs in the 55 patients who received KHK4083 were mild or moderate chills (9.1%), and infusion/injection site reactions (7.3%). "
5.	Injection Site Reaction 08/01/2017 - "The most frequent treatment-related AEs in the 55 patients who received KHK4083 were mild or moderate chills (9.1%), and infusion/injection site reactions (7.3%). "

Related Drugs and Biologics

1.	Monoclonal Antibodies

Related Therapies and Procedures

1.	Intravenous Infusions